Navigation Links
Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
Date:11/18/2009

rly indicated," said Stephen Tyring, MD, PhD, Clinical Professor at the University of Texas Health Sciences Center, the lead investigator of the study.

There were no differences in significant adverse events between valomaciclovir and valacyclovir groups. The most common adverse event in all patient groups was nausea. No patient discontinued treatment due to adverse events related to EPB-348 use.

"We are pleased with our Phase 2b results that demonstrate once-daily EPB-348 is both safe and active in treating shingles. We are encouraged by the trends to better pain resolution and less severe pain in the valomaciclovir-treated patients. We anticipate that EPB-348 may be the first once-a-day shingles drug with a wider treatment window and a reduction in both the incidence and severity of shingles associated pain. We look forward to demonstrating these and other additional benefits in Phase 3 clinical trials," said Fred Volinsky, MD, Epiphany Biosciences' CEO.

EPB-348 has also been shown to be effective against acute infectious mononucleosis, for which there is no FDA-approved treatment, in a Phase 2a study. Data from this study were presented during the 2009 ICAAC meeting in San Francisco.

About EPB-348

EPB-348 is a potent inhibitor of herpes viruses, including the varicella zoster and Epstein-Barr viruses. It has been studied clinically in both shingles and infectious mononucleosis.

About Shingles

Shingles is a reactivation of the varicella zoster virus, the same virus that causes chickenpox in children, and infects over 90% of the US adult population. An estimated 5 in 1000 people suffer from shingles in the US every year, and 20% of all individuals are estimated to experience at least one episode of shingles during their lifetime. The risk of shingles outbreak dramatically increases with age.

Shingles manifests itself as a painful rash that develop into blis
'/>"/>

SOURCE Epiphany Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... DUBLIN , July 27, 2015 /PRNewswire/ ... has announced the addition of the ... Competitors And Opportunities: 2015-2020 Analysis And Forecasts" ... Comprehensive information and evaluation of the ... analysis of manufacturers, segmentation, product offerings, competitive ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
(Date:7/27/2015)... 2015 Syneron Medical Ltd. ... market leader in the aesthetic medical device marketplace, announced ... and Drug Safety (MFDS) regulatory clearance for the PicoWay® ... fulfill PicoWay orders from its Korean distribution partner, with ... the third quarter 2015. Amit Meridor, Chief ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... Ortho-McNeil to Continue Investigation of GDIR Agonists Under its ... ... 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... discovered by Arena and being investigated,for the treatment of type ...
... Phase 2 Program to Provide Initial Proof-of-Concept Data ... ... 7 VIA Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused ... today that,it has enrolled the first patient in its Phase 2 ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 2VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 3VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 5
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... water brands also made the organization’s list. As its name clearly indicates, 10 Best ... Here is a description of the top three brands, along with a listing of ...
(Date:7/27/2015)... ... ... In a creative effort to provide clear information about the process of ... Dove Tree in Lubbock has shared a new infographic to illustrate the process. The ... the nationally recognized collegiate program and traditional adult program at The Ranch at Dove ...
(Date:7/27/2015)... ... July 27, 2015 , ... The new ... diagnostics applications is rapidly increasing and is driven by focused research of pharmaceutical ... increasingly being evaluated for use in bio implants. MWCNTs are used in the ...
(Date:7/27/2015)... ... July 27, 2015 , ... SupplyLogic, a marketing execution ... on its newly redesigned company Website. In the blog, Founder and CEO Kevin Sherlock ... popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer you get ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2
... and relationships have helped many children reduce their levels of ... in August 2005, according to a new study. A second ... in the aftermath of the storm. The studies appear ... July/August 2010 issue of the journal Child Development . ...
... who survived the 2004 tsunami and ongoing civil war there ... to the youths, psychological health, but also daily stressors like ... after the disasters. The studies appear in a special ... of the journal Child Development . The first ...
... University of Texas MD Anderson Cancer Center remains the leading hospital ... according to the annual "Best Hospitals" survey published by U.S. News ... last nine years that MD Anderson has ranked number one in ... has been ranked one of the top two cancer hospitals in ...
... milk be avoided in the early months of an infant,s ... until baby starts eating solid food. But new research from ... cow,s milk in the first 15 days of life may ... Prof. Yitzhak Katz of Tel Aviv University,s Department of Pediatrics, ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, July 14 ... helps people drop pounds but does so with few side ... fighting the obesity epidemic, lorcaserin is a new type of ... associated with feelings of well-being and feeling full, and does ...
... HealthDay Reporter , WEDNESDAY, July 14 (HealthDay News) ... for Alzheimer,s disease for the first time in 25 years ... key change would put more focus on the various stages ... convened by the U.S. National Institute on Aging and the ...
Cached Medicine News:Health News:Hurricane Katrina's effects on children: Resilience and gender 2Health News:Sri Lankan children affected by war, tsunami, daily stressors 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 3Health News:Cow's milk does a baby good 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 3Health News:New Criteria for Alzheimer's Diagnosis Proposed 2Health News:New Criteria for Alzheimer's Diagnosis Proposed 3
... incubator with microprocessor-controlled 6-sided heating. Heated ... HEPA filtered CO2 inlet and fanless ... large character temperature and % CO2 ... mulitple temperature monitors ensure consistent conditions. ...
... represents the top-of-the line incubator ... against contamination is provided by ... the incubation chamber. Water for ... 60-95% r.H. is sterilized at ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO2 Incubator...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Medicine Products: